![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » European Commission Approves Merck’s Keytruda for Squamous Cell Carcinoma
European Commission Approves Merck’s Keytruda for Squamous Cell Carcinoma
December 3, 2019
The European Commission gave its nod to Merck’s Keytruda as a monotherapy or in combination with chemotherapy for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.
The approval was based on the results of a phase 3 clinical trial, in which the drug demonstrated a significant improvement in overall survival as a monotherapy and in combination with chemotherapy compared to standard treatment.
The approval makes Keytruda the first anti-PD-1 treatment option as a first-line treatment for metastatic or unresectable recurrent head and neck cancer.
Upcoming Events
-
21Oct